Indiana University Researchers Find Precision Medicine Improves Outcomes

Milan Radovich, PhD, and Bryan Schneider, MD
Published: Friday, Oct 14, 2016
Milan Radovich, PhD
Milan Radovich, PhD
Assistant Professor
Surgery & Medical and Molecular Genetics
IU School of Medicine
Breast cancer researcher, IU Simon Cancer Center
Co-director, IU Health Precision Genomics Program
Bryan Schneider, MD
Bryan Schneider, MD
Associate Professor
Medicine & Medical and Molecular Genetics
Vera Bradley Investigator in Oncology, IU School of Medicine
Breast cancer researcher, IU Simon Cancer Center
Director, IU Health Precision Genomics Program
Strategic Partnership
Given that cancer at its essence is a disease of DNA, driven by mutations in tumor suppressors and oncogenes, genomics-based precision medicine is a natural fit for oncology therapeutics.

A molecular tumor board composed of oncologists, scientists, pharmacists, pathologists, genetic counselors, and bioethicists reviews each patient’s results to derive a therapeutic plan. Patients return to clinic to receive a layman’s education on their genomic results and counseling for the drugs that are recommended and/or logistical support for pertinent clinical trials. All results and recommendations are subsequently conveyed to their primary oncologist.

Genomic Analysis Improves Outcomes

Our group recently published our experience from the first 101 patients enrolled in the program (Radovich et al. Oncotarget; 2016). The majority of patients had a diagnosis of soft tissue sarcoma, breast cancer, pancreatic cancer, or colorectal cancer, although multiple other tumor types were included.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication